NYSE · Health care

Volitionrx Ltd (VNRX)

Volitionrx Ltd brought in $2.5M of revenue over the twelve months to June 30, 2026, up 86.3% from a year earlier. It posted a net loss of $25.6M. In fiscal 2025 capital spending exceeded operating cash flow by $19.8M. At June 30, 2026 it held $2.8M in cash against $7.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$0.26

+5.37% on the day · September 25, 2026

52-week range $0.23 to $14.80

Market cap

$3.5M

Revenue (last 12 months)

$2.5M

+86.3% year on year

Net margin

-1,043.1%

What Volitionrx Ltd does

Volitionrx Ltd is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NYSE under the ticker VNRX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$1.7M	-$21.7M	-$23.4M	n/a	-$19.8M
2024	$1.2M	-$27M	-$27M	-$0.31	-$26.2M
2023	$775.3K	-$36M	-$35.7M	-$0.50	-$19.1M
2022	$306.4K	-$31.8M	-$30.6M	n/a	-$16.8M
2021	$90K	-$28.3M	-$27M	-$0.51	-$21.8M
2020	$13.4K	-$21.2M	-$20.4M	-$0.45	-$18.4M

Next report expected around October 20, 2026.

Estimated from its filing rhythm: about 68 days after its last report of August 13, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where VNRX ranks in Health care

Revenue$1.7M

#550 of 646 in Health care · Bottom 15%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Volitionrx Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 25, 2026
Unregistered share sale 8-K
September 16, 2026
Activist stake changed SCHEDULE 13D/A
September 15, 2026
Unregistered share sale 8-K
September 14, 2026
Other event 8-K
September 9, 2026
Shelf registration to sell securities (amended) S-3/A
September 8, 2026
Shelf registration to sell securities (amended) S-3/A
September 4, 2026
Activist stake (5% or more) SCHEDULE 13D
September 2, 2026
Material agreement 8-K
September 2, 2026
Unregistered share sale 8-K
August 28, 2026
Shelf registration to sell securities S-3

Recent insider filings (Forms 3, 4 and 144): 10, the latest on March 19, 2026. Insider transactions on SEC

Who owns VNRX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Lagoda Investment Management, L.P.13D, may seek influence with 2 related filers	5.9%	1,650,505	September 16, 2026

Latest filings below 5%: Armistice Capital, LLC 4.99% (February 17, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about VNRX

What does Volitionrx Ltd do?

Volitionrx Ltd is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NYSE under the ticker VNRX.

Is Volitionrx Ltd profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $25.6M on revenue of $2.5M.

How much revenue does Volitionrx Ltd make?

Over the twelve months to June 30, 2026 Volitionrx Ltd reported revenue of $2.5M. That is 86.3% more than a year earlier.

When did Volitionrx Ltd last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the unregistered share sale from September 25, 2026.

Similar companies

IDXX

Idexx Laboratories Inc

QDEL

QuidelOrtho Corp

LNTH

Lantheus Holdings, Inc.

Intellia Therapeutics, Inc.

Compare VNRX with

Compare VNRX with any company

Follow VNRX

Get an email when Volitionrx Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow VNRX: get an email when it files

Where the numbers come from

Financial figures are the values Volitionrx Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.